Cancer Genetics (NASDAQ:CGIX) Shares Down 6%

Share on StockTwits

Cancer Genetics Inc (NASDAQ:CGIX) was down 6% on Thursday . The company traded as low as $0.17 and last traded at $0.18, approximately 966,695 shares traded hands during mid-day trading. A decline of 45% from the average daily volume of 1,767,514 shares. The stock had previously closed at $0.19.

The stock has a market cap of $10.99 million, a P/E ratio of -0.27 and a beta of 1.48. The business has a fifty day moving average of $0.17. The company has a debt-to-equity ratio of 0.24, a current ratio of 0.36 and a quick ratio of 0.36.

Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings data on Monday, May 20th. The medical research company reported ($0.08) earnings per share for the quarter. Cancer Genetics had a negative return on equity of 175.72% and a negative net margin of 77.28%. The firm had revenue of $6.84 million during the quarter.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Cancer Genetics by 106.6% in the 4th quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock worth $53,000 after purchasing an additional 114,448 shares during the period. Virtu Financial LLC bought a new stake in Cancer Genetics in the 1st quarter worth approximately $48,000. Finally, Perkins Capital Management Inc. grew its position in Cancer Genetics by 649.9% in the 1st quarter. Perkins Capital Management Inc. now owns 3,136,528 shares of the medical research company’s stock worth $753,000 after purchasing an additional 2,718,278 shares during the period. Institutional investors own 10.60% of the company’s stock.

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

See Also: Moving Average Convergence Divergence (MACD)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.